Phytohealth Corp
PhytoHealth Corporation researches, develops, manufactures, and sells medicines, cosmetics, Class B medicines, complementary foods, and other related products in Taiwan. It operates in three segments: Medicines and Health Food, Medical Diagnosis, and Precision Medical Equipment and Instruments. The Medicines and Health Food segment manufactures and sells Chinese medicine materials and new drugs. … Read more
Phytohealth Corp (4108) - Net Assets
Latest net assets as of September 2025: NT$2.27 Billion TWD
Based on the latest financial reports, Phytohealth Corp (4108) has net assets worth NT$2.27 Billion TWD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$2.34 Billion) and total liabilities (NT$63.54 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$2.27 Billion |
| % of Total Assets | 97.28% |
| Annual Growth Rate | 13.5% |
| 5-Year Change | 39.14% |
| 10-Year Change | 3.12% |
| Growth Volatility | 72.13 |
Phytohealth Corp - Net Assets Trend (2002–2024)
This chart illustrates how Phytohealth Corp's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Phytohealth Corp (2002–2024)
The table below shows the annual net assets of Phytohealth Corp from 2002 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$2.37 Billion | +4.30% |
| 2023-12-31 | NT$2.27 Billion | -0.30% |
| 2022-12-31 | NT$2.28 Billion | -4.65% |
| 2021-12-31 | NT$2.39 Billion | +40.33% |
| 2020-12-31 | NT$1.70 Billion | -2.83% |
| 2019-12-31 | NT$1.75 Billion | -9.93% |
| 2018-12-31 | NT$1.94 Billion | -6.39% |
| 2017-12-31 | NT$2.08 Billion | -10.27% |
| 2016-12-31 | NT$2.32 Billion | +0.82% |
| 2015-12-31 | NT$2.30 Billion | -3.84% |
| 2014-12-31 | NT$2.39 Billion | -12.81% |
| 2013-12-31 | NT$2.74 Billion | -1.56% |
| 2012-12-31 | NT$2.78 Billion | +78.06% |
| 2011-12-31 | NT$1.56 Billion | -14.23% |
| 2010-12-31 | NT$1.82 Billion | -9.40% |
| 2009-12-31 | NT$2.01 Billion | +100.32% |
| 2008-12-31 | NT$1.00 Billion | -33.93% |
| 2007-12-31 | NT$1.52 Billion | +15.01% |
| 2006-12-31 | NT$1.32 Billion | +11.17% |
| 2005-12-31 | NT$1.19 Billion | +303.81% |
| 2004-12-31 | NT$294.31 Million | -11.36% |
| 2003-12-31 | NT$332.05 Million | +127.40% |
| 2002-12-31 | NT$146.02 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Phytohealth Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 26460700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | NT$1.99 Billion | 104.46% |
| Other Comprehensive Income | NT$174.76 Million | 9.19% |
| Other Components | NT$5.02 Million | 0.26% |
| Total Equity | NT$1.90 Billion | 100.00% |
Phytohealth Corp Competitors by Market Cap
The table below lists competitors of Phytohealth Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ten Sixty Four Ltd
AU:X64
|
$64.47 Million |
|
Viva Wine Group AB
ST:VIVA
|
$64.47 Million |
|
DFV Deutsche Familienversicherung AG
XETRA:DFV
|
$64.48 Million |
|
Harleysville Financial Corp
OTCQX:HARL
|
$64.49 Million |
|
K Laser Technology Inc
TW:2461
|
$64.46 Million |
|
Taiwan Line Tek Electronic Co Ltd
TW:2462
|
$64.46 Million |
|
Hanshin Const
KO:004960
|
$64.46 Million |
|
Cash Converters International
AU:CCV
|
$64.44 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Phytohealth Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,927,106,000 to 1,901,360,000, a change of -25,746,000 (-1.3%).
- Net loss of 73,501,000 reduced equity.
- New share issuances of 628,000 increased equity.
- Other comprehensive income increased equity by 43,898,001.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-73.50 Million | -3.87% |
| Share Issuances | NT$628.00K | +0.03% |
| Other Comprehensive Income | NT$43.90 Million | +2.31% |
| Other Changes | NT$3.23 Million | +0.17% |
| Total Change | NT$- | -1.34% |
Book Value vs Market Value Analysis
This analysis compares Phytohealth Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.40x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.80x to 1.40x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2009-12-31 | NT$16.71 | NT$13.40 | x |
| 2010-12-31 | NT$12.50 | NT$13.40 | x |
| 2011-12-31 | NT$11.18 | NT$13.40 | x |
| 2012-12-31 | NT$19.48 | NT$13.40 | x |
| 2013-12-31 | NT$15.22 | NT$13.40 | x |
| 2014-12-31 | NT$13.28 | NT$13.40 | x |
| 2015-12-31 | NT$12.22 | NT$13.40 | x |
| 2016-12-31 | NT$11.15 | NT$13.40 | x |
| 2017-12-31 | NT$9.96 | NT$13.40 | x |
| 2018-12-31 | NT$8.66 | NT$13.40 | x |
| 2019-12-31 | NT$7.72 | NT$13.40 | x |
| 2020-12-31 | NT$7.61 | NT$13.40 | x |
| 2021-12-31 | NT$10.12 | NT$13.40 | x |
| 2022-12-31 | NT$9.61 | NT$13.40 | x |
| 2023-12-31 | NT$9.70 | NT$13.40 | x |
| 2024-12-31 | NT$9.57 | NT$13.40 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Phytohealth Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -3.87%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -47.86%
- • Asset Turnover: 0.06x
- • Equity Multiplier: 1.28x
- Recent ROE (-3.87%) is above the historical average (-7.51%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | 0.18% | 1.92% | 0.09x | 1.02x | NT$-116.66 Million |
| 2006 | 0.87% | 7.59% | 0.11x | 1.02x | NT$-120.58 Million |
| 2007 | 1.92% | 13.05% | 0.13x | 1.12x | NT$-112.18 Million |
| 2009 | -13.63% | -269.23% | 0.05x | 1.08x | NT$-462.92 Million |
| 2010 | -12.09% | -199.36% | 0.06x | 1.07x | NT$-393.08 Million |
| 2011 | -11.09% | -109.66% | 0.09x | 1.08x | NT$-323.39 Million |
| 2012 | -3.78% | -58.41% | 0.06x | 1.05x | NT$-378.35 Million |
| 2013 | -7.13% | -126.19% | 0.05x | 1.10x | NT$-439.57 Million |
| 2014 | -14.36% | -354.56% | 0.04x | 1.11x | NT$-545.73 Million |
| 2015 | -9.87% | -970.06% | 0.01x | 1.13x | NT$-409.73 Million |
| 2016 | -10.34% | -777.41% | 0.01x | 1.29x | NT$-382.59 Million |
| 2017 | -12.28% | -382.16% | 0.02x | 1.30x | NT$-374.37 Million |
| 2018 | -12.49% | -169.77% | 0.05x | 1.42x | NT$-328.59 Million |
| 2019 | -13.12% | -179.01% | 0.05x | 1.44x | NT$-301.22 Million |
| 2020 | -9.24% | -129.24% | 0.05x | 1.41x | NT$-247.02 Million |
| 2021 | -3.94% | -46.18% | 0.07x | 1.25x | NT$-276.09 Million |
| 2022 | -6.03% | -84.92% | 0.06x | 1.24x | NT$-305.83 Million |
| 2023 | -2.44% | -29.00% | 0.07x | 1.22x | NT$-239.83 Million |
| 2024 | -3.87% | -47.86% | 0.06x | 1.28x | NT$-263.64 Million |
Industry Comparison
This section compares Phytohealth Corp's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $4,528,453,600
- Average return on equity (ROE) among peers: 3.91%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Phytohealth Corp (4108) | NT$2.27 Billion | 0.18% | 0.03x | $64.47 Million |
| Grape King Bio Ltd (1707) | $11.79 Billion | 12.28% | 0.30x | $413.97 Million |
| Standard Chemical & Pharmaceutical Co Ltd (1720) | $8.14 Billion | 10.26% | 0.37x | $160.24 Million |
| Maywufa Co Ltd (1731) | $2.11 Billion | 8.22% | 0.51x | $41.33 Million |
| Allied Biotech Corporation (1780) | $1.17 Billion | 8.33% | 0.78x | $47.92 Million |
| ScinoPharm Taiwan Ltd (1789) | $9.38 Billion | 5.16% | 0.21x | $180.77 Million |
| GeneFerm Biotechnology Co Ltd (1796) | $396.19 Million | 1.14% | 1.48x | $24.30 Million |
| Easywell Biomedicals Inc. (1799) | $696.90 Million | -39.00% | 0.68x | $62.14 Million |
| LIWANLI Innovation Co Ltd (3054) | $799.59 Million | 4.48% | 0.55x | $49.55 Million |
| YungShin Global Holding Corp (3705) | $4.70 Billion | 6.21% | 0.18x | $292.12 Million |
| TTY Biopharm Co Ltd (4105) | $6.11 Billion | 22.00% | 0.56x | $486.74 Million |